Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

ALNY

$158.00

Updated: 03/11/2026, 09:26:18

Market Cap
$21.16B
Sector
Healthcare
Industry
Biotechnology
Country
US

No historical data available

Company Profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

USD
NASDAQ
CEO: Yvonne L. Greenstreet
Employees: 2,500
https://www.alnylam.com
Asset Summaries
Latest generated summaries for ALNY

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
ALNY-10-k-fy2025.html2.9 MBtext/htmlENFiled 12/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 67 KPI observations

Revenue

$3.7B

FY 2025 · Reported

Net income

$0.3B

FY 2025 · Reported

Gross margin

81.8%

FY 2025 · Calculated

Free cash flow

$0.5B

FY 2025 · Calculated

R&D intensity

35.5%

FY 2025 · Calculated

Share repurchases

N/A

FY — · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

AMVUTTRA approved for ATTR-CM
AMVUTTRA approved for ATTR-CM in multiple jurisdictions
Approved and investigational RNAi therapeutic products
Phase 3 pipeline candidate: nucresiran for ATTR-CM
Cost of collaborations includes GalNAc commercial drug supplies

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Collaboration revenue model

Revenue earned under collaboration agreements for technology platform use; ASC 606 vs ASC 808 assessment at inception

95%
Source evidence
“We earn revenue in connection with collaboration agreements that allow our collaborators to utilize our technology platforms and develop product candidates.”

Commercial portfolio: four launched products plus two collaborator-commercialized products

Four commercially launched products and two additional products being commercialized by collaborators

95%
Source evidence
“Although we have commercially launched four products and have two additional products being commercialized by our collaborators”

AMVUTTRA approved for ATTR-CM

AMVUTTRA received FDA approval in March 2025 for ATTR-CM and approvals in certain ex-U.S. jurisdictions during 2025

98%
Source evidence
“AMVUTTRA for the treatment of ATTR-CM following our receipt of regulatory approval from the FDA in March 2025 and in certain jurisdictions outside of the U.S. during the remainder of 2025”

AMVUTTRA approved for ATTR-CM in multiple jurisdictions

AMVUTTRA approved by FDA, EC, PMDA and MHRA for ATTR-CM; other jurisdictions pending

95%
Source evidence
“although AMVUTTRA has been approved by the FDA, EC, PMDA, MHRA and certain other regulatory authorities for the treatment of ATTR-CM, regulatory authorities in other jurisdictions have not yet granted approval for this expanded indication”

Approved and investigational RNAi therapeutic products

Approved products AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO; pipeline including Qfitlia (fitusiran), zilebesiran, mivelsiran, nucresiran, cemdisiran; collaborator products Leqvio (inclisiran), Qfitlia

95%
Source evidence
“our approved and investigational RNAi therapeutics and those of our collaborators, including AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio® (inclisiran), Qfitlia™ (fitusiran), zilebesiran, mivelsiran, nucresiran and cemdisiran”

Phase 3 pipeline candidate: nucresiran for ATTR-CM

Phase 3 clinical trial of nucresiran for the treatment of ATTR-CM faces enrollment challenges due to competing approved therapies

95%
Source evidence
“our Phase 3 clinical trial of nucresiran for the treatment of ATTR-CM because there are multiple approved therapies on the market and multiple investigational therapies in ongoing clinical trials for ATTR-CM”

Cost of collaborations includes GalNAc commercial drug supplies

Collaboration costs include GalNAc material supplied to collaborators and royalties owed on licensed product net sales

90%
Source evidence
“costs we incur in connection with providing commercial drug supplies, such as GalNAc material, to collaborators”

Global commercial infrastructure with U.S. and ex-U.S. launches

Continuing product launches of AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO and continued build-out of global commercial infrastructure

80%
Source evidence
“our plans for additional global regulatory filings and the continuing product launches of AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO”

Operations and dependencies

Norton, Massachusetts manufacturing facility

Norton, MA facility (completed 2020); December 2025 announced meaningful capacity expansion

95%
Source evidence
“In December 2025, we announced a planned expansion of the Norton facility designed to increase capacity meaningfully, significantly reduce production costs”

Reliance on third-party CMOs

Relies on a limited number of CMOs in North America, Europe and Asia for all drug product requirements

97%
Source evidence
“we rely on third party CMOs for all of our drug product requirements for clinical and commercial use. There are a limited number of CMOs worldwide with the expertise to manufacture our siRNA therapeutic products”

Positioning and strategy

RNAi/siRNA competitors named

Named competitors developing chemically synthesized siRNAs include ADARx, Amgen, Arrowhead, AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sarepta, Takeda, Wave Life Sciences and others

95%
Source evidence
“Companies working on chemically synthesized siRNAs include, but are not limited to, ADARx Pharmaceuticals, Inc., Amgen Inc., Argo Biopharmaceutical Co., Ltd., Aro Biotherapeutics, Arrowhead and its collaborators, AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, SanegeneBio, Sarepta Therapeutics, Inc., Silence Therapeutics plc, Takeda Pharmaceutical Company Ltd., and Wave Life Sciences, Ltd.”

Antisense competition: Ionis WAINUA (eplontersen) approved for hATTR using licensed GalNAc technology

Ionis's WAINUA (eplontersen) is approved for hATTR polyneuropathy; Ionis uses Alnylam-licensed GalNAc technology

95%
Source evidence
“Akcea Therapeutics, Inc., a wholly owned subsidiary of Ionis, has received marketing approval for an antisense drug, inotersen, for the treatment of adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy. Several antisense drugs developed by Ionis have been approved and are currently marketed, including WAINUA (eplontersen)”

RNAi delivery expansion across tissues

Leveraging new RNAi and siRNA delivery technologies to liver, CNS, eye, lung, adipose, muscle and other tissues

90%
Source evidence
“continue to leverage new technologies related to both RNAi and to the delivery of siRNAs to the relevant tissues and cells, including the liver, CNS, eye, lung, adipose, muscle and other tissues”

Pipeline expansion to additional tissue types and disease indications

R&D programs across a broad range of disease areas and indications, with plans to expand into additional tissue types

85%
Source evidence
“the potential for improved product profiles to emerge from our technologies and our ability to expand our clinical development pipeline to include additional tissue types and disease indications”

Alnylam 2030 strategy

Alnylam 2030 strategy targets ATTR leadership, sustainable innovation, and sustained profitable growth

95%
Source evidence
“To execute our business plan of achieving leadership in ATTR amyloidosis, driving sustainable innovation, and delivering sustained, profitable growth under our Alnylam 2030 strategy”

Alnylam 2030 strategy development timing

Development timing goals are reflected in the Alnylam 2030 strategy

85%
Source evidence
“as well as lead us to fail to achieve our intended development timing, including as reflected in our Alnylam 2030 strategy”

Risks, financing, and outlook

Convertible Notes outstanding: $1.02 billion

$1.02 billion aggregate principal of convertible Notes outstanding as of December 31, 2025; 2027 Notes at 1.00% fixed, 2028 Notes non-interest bearing

97%
Source evidence
“As of December 31, 2025, we had $1.02 billion in total aggregate principal amount of Notes issued and outstanding. The interest rate for the 2027 Notes is fixed at 1.00% per annum and is payable semi-annually in arrears on March 15 and September 15 of each year. The 2028 Notes do not bear regular interest.”

Liabilities related to sale of future royalties and development funding

Future-royalty sale and development funding liabilities treated as debt; estimates depend on projected Leqvio and AMVUTTRA global net revenues

95%
Source evidence
“We account for the liabilities related to the sale of future royalties and development funding as debt financings. Interest on these liabilities is recognized using the effective interest rate method over the repayment period.”

Convertible notes outstanding

1.00% Convertible Senior Notes due 2027 and 0.00% Convertible Senior Notes due 2028 with liquidity/settlement risks

95%
Source evidence
“1.00% Convertible Senior Notes due 2027, or the 2027 Notes, or to repurchase the 2027 Notes or our 0.00% Convertible Senior Notes due 2028, or the 2028 Notes”

Capped call transactions on convertible notes

Capped call transactions related to convertible notes with option counterparties

85%
Source evidence
“our expectations regarding the effect of the capped call transactions and the anticipated market activities of the option counterparties and/or their respective affiliates”

AMVUTTRA regulatory expansion for ATTR amyloidosis with cardiomyopathy

Seeking approval of AMVUTTRA (vutrisiran) for ATTR amyloidosis with cardiomyopathy in additional jurisdictions outside the United States

90%
Source evidence
“our ability to obtain regulatory approval of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy in additional jurisdictions outside the United States”

Cash runway based on current operating plan

Company discloses expectations for how long current cash, cash equivalents and marketable debt securities will support operations

75%
Source evidence
“our expectations regarding the length of time our current cash, cash equivalents and marketable debt securities will support our operations based on our current operating plan”

Convertible debt repurchase (1.00% notes) under ASU 2024-04

Adopted ASU 2024-04 (induced conversions) in Q3 2025; applied to repurchase of 1.00% convertible debt

90%
Source evidence
“we applied the guidance to the repurchase of our 1.00% Co”

BIOSECURE ACT enacted December 2025

BIOSECURE ACT (Dec 2025, NDAA FY2026) may restrict dealings with certain Chinese biotech companies of concern

95%
Source evidence
“In December 2025, the BIOSECURE ACT was enacted into law as part of the National Defense Authorization Act for fiscal year 2026”

FDA CRL for patisiran sNDA in ATTR-CM (October 2023)

Despite positive APOLLO-B Phase 3 results of patisiran in ATTR-CM, the FDA issued a CRL in October 2023 on the sNDA

95%
Source evidence
“although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR-CM, in October 2023, the FDA issued a CRL in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form”

Healthcare reform and pricing/reimbursement exposure

Exposure to current and potential healthcare reforms affecting delivery, pricing, government price reporting, payment, insurance coverage or reimbursement

85%
Source evidence
“the impact of current and potential healthcare reforms, including those affecting the delivery, pricing or government price reporting of, or payment, insurance coverage or reimbursement for, healthcare products and services”

Mivelsiran Phase 1 on partial clinical hold (Alzheimer's Disease)

Phase 1 trial of mivelsiran for Alzheimer's Disease remains on partial clinical hold in the U.S. due to non-clinical chronic toxicology findings

97%
Source evidence
“our Phase 1 clinical trial of mivelsiran for Alzheimer’s Disease remains on partial clinical hold for certain dosing levels or frequencies in the U.S. due to findings observed in non-clinical chronic toxicology studies”

Revenue concentration in AMVUTTRA

Business dependent on sustaining and growing AMVUTTRA revenues

97%
Source evidence
“In 2025, a significant portion of our net product revenues was derived from the sale of our TTR products, and in particular AMVUTTRA”

Collaboration termination risk - Novartis/Leqvio

Novartis agreement for Leqvio terminable on four months' notice; termination for convenience requires license grant to Alnylam

95%
Source evidence
“may be terminated by Novartis at any time upon four months' prior written notice”

History of losses

History of significant operating losses; may not sustain profitability

95%
Source evidence
“We have experienced significant operating losses since our inceptio”

Technology licensing to Ionis, Benitec, Arrowhead, Arbutus, Sylentis; licenses held by Takeda and Arrowhead (via Novartis)

Alnylam granted RNAi licenses/options to Ionis, Benitec, Arrowhead, Arbutus and Sylentis; Arrowhead holds exclusive licenses for 30 gene targets via Novartis assignment

95%
Source evidence
“Arrowhead, as the assignee of Novartis, has obtained specific exclusive licenses for 30 gene targets, that include access to certain aspects of our technology”

Stock ownership concentration

As of December 31, 2025, seven largest stockholders beneficially own >50% of outstanding common stock

95%
Source evidence
“As of December 31, 2025, our seven largest stockholders beneficially owned in excess of 50% of our outstanding shares of common stock.”

Cash flow may be insufficient to service indebtedness

Cash flow from the business may not be sufficient to pay indebtedness including the convertible Notes

95%
Source evidence
“We may not have sufficient cash flow from our business to pay our indebtedness.”

Pricing and reimbursement pressure

Exposure to MFN pricing, U.S. drug price negotiation, and payor reimbursement restrictions

93%
Source evidence
“including most-favored nation pricing measures, measures requiring the U.S. government in the future to negotiate the prices of certain drugs”

Clinical trial enrollment risk

Patient enrollment difficulties could delay or prevent clinical trials and regulatory approval

93%
Source evidence
“Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval.”

Delivery technology competition risk

Substantial competition to develop safe and effective siRNA delivery; competitors may gain exclusive access to third-party delivery solutions

93%
Source evidence
“we face substantial competition to discover and develop safe and effective means to deliver siRNAs to the relevant cell and tissue types”

Competition in RNAi and emerging technologies

Competition from RNAi-similar platforms, emerging technologies, and competing ATTR therapies

92%
Source evidence
“We and our collaborators face competition from other companies that are working to develop novel drugs and technology platforms using technology similar to ours, as well as from companies utilizing emerging technologies”

FDA funding/priority risk under current administration

FDA funding shortfalls and shifting priorities under the current administration could hinder reviews and approvals

90%
Source evidence
“Inadequate funding for the FDA and other government agencies and/or potentially shifting priorities under the current administration could hinder the agencies’ ability to hire and retain key leadership and other personnel”

Convertible notes refinancing and conversion risk

Company faces obligations to service interest on, refinance, or make cash payments upon conversion of its convertible notes

90%
Source evidence
“our ability to satisfy our payment obligations, and to service the interest on, or to refinance our indebtedness, including our convertible notes, or to make cash payments in connection with any conversion of our convertible notes”

Single/limited-source delivery technology manufacturing

May have access to only one or limited manufacturers for specialized delivery technology

90%
Source evidence
“we may have access to only one or a limited number of potential manufacturers for such delivery technology”

Pharmaceutical tariff exposure

Potential pharmaceutical tariffs of 100%+ could increase COGS and disrupt supply

90%
Source evidence
“has announced plans to impose or increase tariffs of potentially 100% or more on pharmaceuticals”

Securities litigation risk following stock price declines

Potential securities class action litigation risk tied to stock price volatility

90%
Source evidence
“We may be the target of securities litigation that could result in substantial costs and divert our management’s attention and resources”

Manufacturing and supply dependence including contract manufacturers

Risk of delays, interruptions or failures in manufacture and supply of products by the company or its contract manufacturers

85%
Source evidence
“the status of our manufacturing operations and any delays, interruptions or failures in the manufacture and supply of AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO or any of our product candidates”

Competition including generic versions of competing products

Potential impact of competing products, including generic versions, on commercial success of marketed products

85%
Source evidence
“the possible impact of any competing products, including generic versions of competing products, on the commercial success of AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio and Qfitlia”

Third-party reliance for development, manufacture and distribution

Reliance on third parties for development, manufacture and distribution of products

80%
Source evidence
“the ability of the third parties on which we rely for development, manufacture and distribution of our products to meet their obligations to us”

Intellectual property protection

Ability to obtain, maintain and protect intellectual property is a stated forward-looking risk

75%
Source evidence
“our ability to obtain, maintain and protect our intellectual property”

Material exposure graph

AMVUTTRA
Revenue Exposure

Company revenue is concentrated in AMVUTTRA sales for ATTR-CM following March 2025 FDA approval; failure to grow these revenues would materially harm results.

Relevance 95·Dependency 90·Confidence 97
Source evidence
“our business is dependent upon our ability to sustain and grow revenues from sales of AMVUTTRA”
RNAi therapeutics platform
Technology Dependency

All approved products and pipeline candidates derive from the RNAi platform; pipeline expansion into additional tissue types underpins growth.

Relevance 90·Dependency 90·Confidence 90
Source evidence
“our views with respect to the clinical and commercial potential of (including the potential numbers of patients who may benefit from) our approved and investigational RNAi therapeutics”
AMVUTTRA
Revenue Exposure

AMVUTTRA's commercial expansion depends on securing ATTR-CM approval in additional jurisdictions beyond FDA, EC, PMDA and MHRA.

Relevance 90·Dependency 85·Confidence 90
Source evidence
“AMVUTTRA has been approved by the FDA, EC, PMDA, MHRA and certain other regulatory authorities for the treatment of ATTR-CM, regulatory authorities in other jurisdictions have not yet granted approval for this expanded indication”
U.S. Food and Drug Administration
Regulatory Exposure

FDA approval is required for commercialization; agency funding shortfalls and shifting priorities could delay reviews, and past CRL (patisiran ATTR-CM) demonstrates approval uncertainty.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“Inadequate funding for the FDA and other government agencies and/or potentially shifting priorities under the current administration could hinder the agencies’ ability to hire and retain key leadership and other personnel”
AMVUTTRA (vutrisiran)
Demand Driver

AMVUTTRA approval for ATTR amyloidosis with cardiomyopathy in additional jurisdictions is a key growth lever; company explicitly ties future outlook to its regulatory expansion.

Relevance 90·Dependency 85·Confidence 90
Source evidence
“our ability to obtain regulatory approval of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy in additional jurisdictions outside the United States”
Third-party CMOs
Supplier Dependency

All drug product requirements for clinical and commercial use are manufactured by a limited number of CMOs; CMO failure risks commercial supply.

Relevance 85·Dependency 85·Confidence 95
Source evidence
“we rely on third party CMOs for all of our drug product requirements for clinical and commercial use”
siRNA delivery technology
Technology Dependency

Commercial success depends on maintaining leadership in siRNA delivery to relevant cell and tissue types; competitors may lock up exclusive third-party delivery solutions.

Relevance 85·Dependency 80·Confidence 93
Source evidence
“if our competitors negotiate exclusive access to delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates”
nucresiran
Competitive Exposure

Nucresiran ATTR-CM enrollment competes against multiple approved and investigational ATTR-CM therapies, threatening development timelines.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“we may experience delays in recruiting and enrolling patients, and in particular treatment-naive patients, for our Phase 3 clinical trial of nucresiran for the treatment of ATTR-CM because there are multiple approved therapies on the market”
AMVUTTRA
Revenue Exposure

Interest expense on royalty-sale/development funding debt is tied to estimated AMVUTTRA global net revenues, exposing financing costs to AMVUTTRA's commercial performance.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“using third-party data to estimate Leqvio's and AMVUTTRA's global net revenues”
Healthcare reform / pricing and reimbursement
Revenue Exposure

Healthcare reforms affecting pricing, government price reporting, payment, insurance coverage and reimbursement directly affect product revenue.

Relevance 80·Dependency 70·Confidence 85
Source evidence
“the impact of current and potential healthcare reforms, including those affecting the delivery, pricing or government price reporting of, or payment, insurance coverage or reimbursement for, healthcare products and services”
Leqvio
Revenue Exposure

Interest expense on royalty-sale/development funding debt is tied to estimated Leqvio global net revenues, exposing financing costs to Leqvio's commercial performance.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“using third-party data to estimate Leqvio's and AMVUTTRA's global net revenues”
Drug pricing regulation
Regulatory Exposure

MFN pricing, U.S. government drug price negotiation, and payor reimbursement restrictions could reduce net price of AMVUTTRA and other products.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“drug price control measures that have been or may be enacted or introduced in the U.S. by various federal and state authorities”
Ionis Pharmaceuticals
Competitive Exposure

Ionis markets approved antisense drugs (WAINUA/inotersen) for hATTR using Alnylam-licensed GalNAc technology, competing directly in amyloidosis.

Relevance 80·Dependency 60·Confidence 95
Source evidence
“Ionis is also developing antisense drugs using ligand-conjugated GalNAc technology licensed from us, and these drugs have been shown to have increased potency at lower doses in clinical and preclinical studies”
Contract manufacturers
Supplier Dependency

Manufacture and supply of commercial products depends on the company and its contract manufacturers; failures would interrupt product supply.

Relevance 75·Dependency 70·Confidence 85
Source evidence
“delays, interruptions or failures in the manufacture and supply of AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO or any of our product candidates (or Leqvio, Qfitlia, cemdisiran or other products or product candidates being developed and commercialized by our collaborators), by our or their contract manufacturers or by us or our collaborators”
mivelsiran
Regulatory Exposure

Partial clinical hold on mivelsiran Phase 1 in the U.S. could impact development timelines if plans change.

Relevance 75·Dependency 70·Confidence 95
Source evidence
“it is possible that the partial clinical hold could have an impact if our development plans change or that future partial or full clinical holds on mivelsiran or our other product candidates could impact our ability to advance the clinical development”
GalNAc
Technology Dependency

Alnylam supplies GalNAc material commercially to collaborators, linking collaboration cost structure to its GalNAc delivery platform.

Relevance 75·Dependency 65·Confidence 85
Source evidence
“costs we incur in connection with providing commercial drug supplies, such as GalNAc material, to collaborators”
Arrowhead Pharmaceuticals
Competitive Exposure

Arrowhead competes in siRNA therapeutics and holds exclusive licenses to certain Alnylam technology for 30 gene targets via Novartis assignment.

Relevance 75·Dependency 55·Confidence 95
Source evidence
“Arrowhead, as the assignee of Novartis, has obtained specific exclusive licenses for 30 gene targets, that include access to certain aspects of our technology”
siRNA delivery technology (LNPs, conjugates)
Technology Dependency

Specialized/proprietary delivery technologies may be manufacturable by only one or a limited number of suppliers, creating supply risk.

Relevance 70·Dependency 70·Confidence 88
Source evidence
“we may have access to only one or a limited number of potential manufacturers for such delivery technology”
Collaboration partners (Leqvio, Qfitlia, cemdisiran)
Revenue Exposure

Collaborations supply R&D funding, licensing fees, milestones and royalties; maintaining these agreements supports non-product revenue.

Relevance 70·Dependency 55·Confidence 85
Source evidence
“our ability to maintain our existing collaborations and our expectations regarding potential future research and development funding, licensing fees and milestone and royalty payments that we may receive under existing or future collaboration agreements”
BIOSECURE ACT
Regulatory Exposure

BIOSECURE ACT could restrict purchasing from or collaborating with Chinese biotech companies of concern; Alnylam does business with companies in China.

Relevance 70·Dependency 50·Confidence 90
Source evidence
“The BIOSECURE ACT has the potential to severely restrict our ability to purchase services or products from, or otherwise collaborate with, certain Chinese “biotechnology companies of concern””
Pharmaceutical tariffs
Cost Driver

Potential tariffs of 100%+ on pharmaceuticals could increase cost of goods sold and disrupt suppliers.

Relevance 65·Dependency 40·Confidence 88
Source evidence
“any unfavorable tariffs may increase our cost of goods sold”
Indebtedness / convertible notes service
Cost Driver

$1.02 billion of convertible Notes require future cash flow for principal, interest and conversion payments; business may not generate sufficient cash flow.

Relevance 60·Dependency 55·Confidence 90
Source evidence
“Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the Notes, or to make cash payments in connection with any conversions of Notes, depends on our future performance”
Novartis
Revenue Exposure

Novartis commercializes Leqvio under collaboration terminable on four months' notice; termination would require Alnylam to find a new collaborator or build internal commercialization.

Relevance 60·Dependency 50·Confidence 92
Source evidence
“Our agreement with Novartis relating to the development and commercialization of Leqvio worldwide may be terminated by Novartis at any time upon four months’ prior written notice”
Full company information
Latest profile, trading, valuation, and identifier data stored for ALNY.
Share price
$158.00
Market cap
$21.16B
Exchange
NASDAQ
Currency
USD
CEO
Yvonne L. Greenstreet
Employees
2,500
IPO date
01/06/2004
Beta
0.269
Last dividend
$0.00
Day range
$156.00 – $163.90
52-week range
$156.00 – $479.79
1-day performance
-4.24%
1-year performance
1.28%
Current drawdown (1Y)
-67.07%
CIK
0001178670
CUSIP
02043Q107
ISIN
US02043Q1076
Created
07/12/2025, 02:02:09
Last update
03/11/2026, 09:26:18

Track Alnylam Pharmaceuticals, Inc. with an AI analyst

See which prediction-market events move ALNY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to ALNY from your Railway `news_articles` table.

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Zacks Investment Research • STOCK • 12/06/2026, 12:21:14

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 22:22:10

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

Reuters • STOCK • 03/06/2026, 20:05:39

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Business Wire • STOCK • 03/06/2026, 18:45:00

Alnylam Issues 2025 Corporate Responsibility Report

Business Wire • STOCK • 19/05/2026, 10:30:00

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 18:40:51

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

MarketBeat • STOCK • 13/05/2026, 18:15:15

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

Business Wire • STOCK • 12/05/2026, 04:30:00

Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth

Zacks Investment Research • STOCK • 01/05/2026, 15:10:26

Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year

Seeking Alpha • STOCK • 01/05/2026, 14:25:55

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 30/04/2026, 14:51:44

Alnylam (ALNY) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Investment Research • STOCK • 30/04/2026, 13:01:48